2023-503355-98-00
Active, not recruiting
Phase 1/2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients with Prion Disease
Ionis Pharmaceuticals Inc.4 sites in 4 countries8 target enrollmentStarted: October 19, 2023Last updated:
Overview
- Phase
- Phase 1/2
- Status
- Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals Inc.
- Enrollment
- 8
- Locations
- 4
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Global Regulatory Affairs
Scientific
Ionis Pharmaceuticals Inc.
Study Sites (4)
Loading locations...
Similar Trials
Recruiting
Phase 1
A phase I trial evaluating the safety, tolerability, and pharmacokinetic profile of INP12 in patients with advanced solid tumors.2024-518126-32-00Innoup Farma S.L.70
Recruiting
Phase 1
A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults2024-519328-26-01Debiopharm International S.A.88
Active, not recruiting
Phase 1
First-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTX-PID in healthy male volunteers2023-503892-83-00Vivet Therapeutics35
Not yet recruiting
Phase 1
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.2025-523146-27-00Innovative Molecules GmbH30
Recruiting
Phase 1
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPCNCT07259213Radiopharm Theranostics, Ltd73